

Adamas Pharmaceuticals Inc
 Form 4
 June 21, 2017

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 GREAT POINT PARTNERS LLC

2. Issuer Name and Ticker or Trading Symbol
 Adamas Pharmaceuticals Inc
 [ADMS]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
 165 MASON STREET, 3RD FLOOR,
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 06/19/2017

____ Director
 ____ Officer (give title below)
 ___X___ 10% Owner
 ____ Other (specify below)

GREENWICH, CT 06830

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 ___ Form filed by One Reporting Person
 ___X___ Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code V	Amount	(A) or (D)	Price			
Common Stock	06/19/2017		S	D	350,000 (1)	D	\$ 17.0505	2,251,351 (2)	I	Investment Mgr. (3)
Common Stock	06/20/2017		S	D	20,000 (4)	V	\$ 17.3467	2,231,351 (5)	I	Investment Mgr. (3)
Common Stock	06/21/2017		S	D	10,000 (6)	V	\$ 17.4365	2,216,351 (7)	I	Investment Mgr. (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form

SEC 1474
 (9-02)

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Beneficially (Instr. 5)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
GREAT POINT PARTNERS LLC 165 MASON STREET, 3RD FLOOR GREENWICH, CT 06830		X		
JAY JEFFREY R GREAT POINT PARTNERS, LLC 165 MASON STREET, 3RD FLOOR GREENWICH, CT 06830		X		
KROIN DAVID C/O GREAT POINT PARTNERS LLC 165 MASON STREET, 3RD FLOOR GREENWICH, CT 06830		X		

Signatures

Great Point Partners, LLC /s/ Dr. Jeffrey R. Jay, M.D., Senior Managing Member	06/21/2017
_____ **Signature of Reporting Person	Date
/s/ Dr. Jeffrey R. Jay, M.D.	06/21/2017
_____ **Signature of Reporting Person	Date
/s/ David Kroin	06/21/2017
_____ **Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Consists of 94,851 shares owned by Biomedical Value Fund, L.P. ("BVF"), 145,713 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 103,098 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 6,338 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

(2) Consists of 610,121 shares owned by Biomedical Value Fund, L.P. ("BVF"), 937,287 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 663,176 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,767 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

(3) Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

(4) Consists of 5,420 shares owned by Biomedical Value Fund, L.P. ("BVF"), 8,327 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 5,891 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 362 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

(5) Consists of 604,701 shares owned by Biomedical Value Fund, L.P. ("BVF"), 928,960 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 657,285 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,405 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

(6) Consists of 4,065 shares owned by Biomedical Value Fund, L.P. ("BVF"), 6,245 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 4,418 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 272 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

(7) Consists of 600,636 shares owned by Biomedical Value Fund, L.P. ("BVF"), 922,715 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 652,867 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,133 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.